Buscar
01/09/2025
Sex-related differences in the efficacy and toxicity of cancer treatments
Bertrán, AS, Rodríguez, JAM, Cardeña-Gutiérrez, A, Martinez-Callejo, V, Higuera, O, Bernardez, B, Moreno-Martínez, ME, Majem, M. Sex-related differences in the efficacy and toxicity of cancer treatments. Clinical & Translational Oncology. 2025; 27(9)DOI:10.1007/s12094-025-03893-2. PMID:40153220. IF:2.500(Q3/6D).
01/09/2025
[Translated article] Map of the residency rotations for hospital pharmacy residents in Spain
Aguilar, CC, Negro-Vega, E, Gamarra-Martínez, EFD, Castro, BM, Abánades, MP, Capafons, SR, Conde, CPM. [Translated article] Map of the residency rotations for hospital pharmacy residents in Spain. Farmacia Hospitalaria. 2025; 49(5)DOI:10.1016/j.farma.2025.06.010. PMID:40640013. IF:(Q/D).
01/09/2025
Ten-Year Experience in the Joint Dermatology-Rheumatology Approach to Patients With Psoriatic Arthritis
Ferrer, AL, Macias, HC, Sanz, LP, Alonso, AL. Ten-Year Experience in the Joint Dermatology-Rheumatology Approach to Patients With Psoriatic Arthritis. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.06.013. PMID:40570946. IF:(Q/D).
01/09/2025
Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023
Puig, L, Sewerin, P, Schuster, C, Ng, KJ, Papadimitropoulos, M, Gadagamma, S, Nuñez, M, Lampropoulou, A. Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023. ADVANCES IN THERAPY. 2025; 42(9)DOI:10.1007/s12325-025-03258-9. PMID:40676380. IF:4.000(Q1/3D).
01/09/2025
Patient Perspectives on the Impact of Living With Hidradenitis Suppurativa: Results From the Global 'HS Uncovered' Burden of Disease Survey
Kokolakis, G, Vilarrasa, E, Garg, A, Alarcon, I, Go, M, Newbold, G, Mamareli, A, Richardson, C, McGrath, BM, Guillem, P. Patient Perspectives on the Impact of Living With Hidradenitis Suppurativa: Results From the Global 'HS Uncovered' Burden of Disease Survey. Jeadv Clinical Practice. 2025; 4(4)DOI:10.1002/jvc2.70071. PMID:. IF:(Q/D).
01/09/2025
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results
Papp, KA, Lebwohl, MG, Puig, L, Ohtsuki, M, Beissert, S, Gooderham, M, Amin, AZ, Wu, TS, Rubant, S, Bialik, B, Ashley, D, Soliman, AM, Chen, MM, Blauvelt, A. Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2025; 26(5)DOI:10.1007/s40257-025-00964-6. PMID:40728772. IF:8.800(Q1/1D).
01/09/2025
Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice
Butrón-Bris, B, Llamas-Velasco, M, Armesto, S, Sahuquillo-Torralba, A, Pujol-Montcusi, J, Ruiz-Villaverde, R, Martinez-López, A, de la Cueva, P, Romero-Mate, A, Roustan, G, Vilarrasa-Rull, E, Ferrán-Farres, M, Ovejero-Benito, MC, Palomar-Moreno, C, Navares, M, Novalbos, J, Abad-Santos, F, Dauden, E, de la Fuente, H. Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.03.030. PMID:40246146. IF:(Q/D).
01/09/2025
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Blauvelt, A, Langley, RG, Lebwohl, M, Strober, B, Warren, RB, Puig, L, Morita, A, Gordon, KB, Fernandez-Peña, P, Kavanagh, S, Pinto, JML, Lambert, J, Hoepken, B, Deherder, D, Cross, N, Thaçi, D. Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:10.1016/j.jaad.2025.04.038. PMID:40286813. IF:11.800(Q1/1D).
01/09/2025
Cryopreserved Total Skin Allografts From Living Donors for Complex Wound Management: A New Paradigm in Regenerative Wound Care
Fonseca, M, Cañete, A, Mandriaza, L, Gomez, J, Masiá, J, Marcelain, K, Ibaceta, D, Erazo, C, Gámez, B, Rius, M, Disi, F. Cryopreserved Total Skin Allografts From Living Donors for Complex Wound Management: A New Paradigm in Regenerative Wound Care. International Wound Journal. 2025; 22(9)DOI:10.1111/iwj.70759. PMID:40890023. IF:2.500(Q1/3D).
01/09/2025
Robot-assisted vs open kidney transplantation from deceased donors
Afferi, L, Territo, A, Pecoraro, A, Masieri, L, Ortved, M, Dagnaes-Hansen, JA, Etcheverry, B, Gallioli, A, Cannoletta, D, Vangeneugden, J, Mercier, J, Prudhomme, T, Donnini, I, Vazzana, A, Rohrsted, M, Vigues, F, Doumerc, N, Decaestecker, K, Palou, J, Campi, R, Serni, S, Roder, A, Breda, A. Robot-assisted vs open kidney transplantation from deceased donors. BJU INTERNATIONAL. 2025; 136(3)DOI:10.1111/bju.16799. PMID:40415630. IF:4.400(Q1/2D).
01/09/2025
Injection density in Rezum®: Less might not be more. A multicentric international study
Schwartzmann, I, Secco, S, Farré, A, García-Barreras, S, Fernández, E, D'Anna, M, Cindolo, L, Parejo, V, Tornero, JI, Ferrari, G, Varvello, F, de León, JP, Povo, I. Injection density in Rezum®: Less might not be more. A multicentric international study. Actas Urologicas Espanolas. 2025; 49(7)DOI:10.1016/j.acuro.2025.501824. PMID:40752731. IF:1.200(Q3/7D).
01/09/2025
New insights and emerging approaches in bladder-sparing treatment for muscle-invasive bladder cancer
Subiela, JD, Guerrero-Ramos, F, Rodríguez-Faba, O, Aumatell, J, Gajate, P, López-Campos, F, Sevillano, E, Hernández-Arroyo, M, García-Rojo, E, Medina, AA, Sáenz-Calzada, D, Gómez-Cañizo, C, Romero-Otero, J, Couñago, F. New insights and emerging approaches in bladder-sparing treatment for muscle-invasive bladder cancer. Actas Urologicas Espanolas. 2025; 49(7)DOI:10.1016/j.acuro.2025.501758. PMID:40258413. IF:1.200(Q3/7D).
01/09/2025
Clinical Practices and Perspectives on Prostate Biopsy Techniques Among Urologists: A European Survey
Uleri, A, Diamand, R, Fiard, G, Sanguedolce, FC, Olivier, J, Renard-Penna, R, Peyrottes, A, Ploussard, G, Baboudjian, M. Clinical Practices and Perspectives on Prostate Biopsy Techniques Among Urologists: A European Survey. European Urology Oncology. 2025; 8(4)DOI:10.1016/j.euo.2025.05.009. PMID:40425419. IF:9.300(Q1/1D).
01/09/2025
Impact of Histological Subtypes/Divergent Differentiation on Clinicopathological and Oncological Outcomes for Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Comprehensive Updated Systematic Review and Meta-analysis
Krajewski, W, Nowak, L, Laszkiewicz, J, Chorbinska, J, Tomczak, W, Gurwin, A, Moschini, M, Pradere, B, Gallioli, A, Subiela, JD, Laukhtina, E, Del Giudice, F, Marcq, G, Afferi, L, Krajewska, M, Khan, MS, Nair, R, Malkiewicz, B, Szydelko, T. Impact of Histological Subtypes/Divergent Differentiation on Clinicopathological and Oncological Outcomes for Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Comprehensive Updated Systematic Review and Meta-analysis. European Urology Oncology. 2025; 8(4)DOI:10.1016/j.euo.2025.03.003. PMID:40221279. IF:9.300(Q1/1D).
01/09/2025
Is SBRT the optimal first-line treatment for operable early-stage NSCLC in elderly patients?
Soto-Cambres, AM, Farré, N. Is SBRT the optimal first-line treatment for operable early-stage NSCLC in elderly patients?. Clinical & Translational Oncology. 2025; 27(9)DOI:10.1007/s12094-025-03914-0. PMID:40221951. IF:2.500(Q3/6D).
01/09/2025
Uncertainty experienced by the critical patient upon discharge to the general ward: Care proposals from the perspective of Mishel's theory
Romero-Pastor, M, Ricart-Basagaña, MT, Mariné-Méndez, A, Lomero-Martínez, MD, Romaní-Alfonso, O, Rubio-Rico, ML. Uncertainty experienced by the critical patient upon discharge to the general ward: Care proposals from the perspective of Mishel's theory. Nursing in Critical Care. 2025; 30(5)DOI:10.1111/nicc.13217. PMID:39822112. IF:2.600(Q1/2D).
01/09/2025
Resident-Performed Coronary Artery Bypass Grafting Using Bilateral Internal Mammary Arteries: Clarifying Methodological Gaps Reply to Ignazio Condello et al
Tauron-Ferrer, M. Resident-Performed Coronary Artery Bypass Grafting Using Bilateral Internal Mammary Arteries: Clarifying Methodological Gaps Reply to Ignazio Condello et al. Interdisciplinary Cardiovascular And Thoracic Surgery. 2025; 40(9)DOI:10.1093/icvts/ivaf202. PMID:40905955. IF:1.300(Q3/7D).
01/09/2025
Rescue stenting after failed mechanical thrombectomy: The RES-CAT study
Collet-Vidiella, R, Camps-Renom, P, Núnez-Guillén, A, Quesada, H, Rizzo, F, Rodriguez-Villatoro, N, Amaro, S, Llull, L, Santana, D, Estrada, E, Flores, A, Terceño, M, Bashir, S, Hernández-Pérez, M, Remollo, S, Barrachina-Esteve, O, Cánovas, D, Vivas, E, Rodríguez-Campello, A, Mauri, G, Purroy, F, Ramos-Pachón, A, Guasch-Jiménez, M, Guisado-Alonso, D, Prats-Sánchez, L, Martínez-Domeño, A, Lambea-Gil, A, Ezcurra-Díaz, G, Branera-Pujol, J, Martínez-González, JP, Dinia, L, Salvat-Plana, M, de la Ossa, NP, Molina, CA, Cardona, P, Martí-Fàbregas, J. Rescue stenting after failed mechanical thrombectomy: The RES-CAT study. European Stroke Journal. 2025; 10(3)DOI:10.1177/23969873241308680. PMID:39745051. IF:4.500(Q1/2D).
01/09/2025
Allostatic overload as the pathophysiological basis for integrating palliative care in the Intensive Care Unit
Forte, DN, Ramos, JGR, Ranzani, OT. Allostatic overload as the pathophysiological basis for integrating palliative care in the Intensive Care Unit. INTENSIVE CARE MEDICINE. 2025; 51(9)DOI:10.1007/s00134-025-08054-1. PMID:40736674. IF:21.200(Q1/1D).
01/09/2025
Flaws and weaknesses in estimating the budget impact of lung cancer screening in Spain
Rosell, A, Estrada, O, López-Seguí, F, Vicente-Gómez, JA, Robledinos-Antón, N, Seijo, LM, Trujillog, JC. Flaws and weaknesses in estimating the budget impact of lung cancer screening in Spain. Gaceta Sanitaria. 2025; 39DOI:10.1016/j.gaceta.2025.102528. PMID:41016098. IF:1.500(Q3/7D).
01/09/2025
IMPACT OF RAMADAN ON OVERDIAGNOSIS OF GESTATIONAL DIABETES: MATCHED CASE-CONTROL ANALYSIS BASED ON CLINICAL REGISTRIES
Real, J, Franch-Nadal, J, Mauricio, D, Vlacho, B, Carrasco, M, Monroy, G, Hernández, M. IMPACT OF RAMADAN ON OVERDIAGNOSIS OF GESTATIONAL DIABETES: MATCHED CASE-CONTROL ANALYSIS BASED ON CLINICAL REGISTRIES. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).
01/09/2025
A recurrent non-coding 3'UTR variant as a hidden second hit in 11 families with CAPN3-related limb girdle muscular dystrophy
Estévez-Arias, B, Segarra-Casas, A, Romo, L, Polavarapu, K, O'Heir, E, Singer-Berk, M, O'Leary, M, Nectoux, J, Spinazzi, M, Leturcq, F, Llanso, L, Domínguez, C, Topf, A, Lochmüller, H, Malfatti, E, Nascimento, A, Gallardo, E, González-Quereda, L, Natera-de Benito, D. A recurrent non-coding 3'UTR variant as a hidden second hit in 11 families with CAPN3-related limb girdle muscular dystrophy. NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105786. PMID:. IF:2.800(Q2/5D).
01/09/2025
International Diabetes Federation 2024 criteria: impact on the postpartum glucose tolerance assessment of women with gestational diabetes
Corcoy, R, Mendoza, LC, Serrano, AC, Bonet, M, Mart nez, A, Romero, M, Safont, E, Pujol, I, Lopez, A. International Diabetes Federation 2024 criteria: impact on the postpartum glucose tolerance assessment of women with gestational diabetes. DIABETOLOGIA. 2025; 68DOI:. PMID:. IF:10.200(Q1/1D).
01/09/2025
Pre-eclampsia is an independent predictor of atherosclerosis progression in women with type 1 diabetes: a 5 year prospective study
Mesa, A, Puig-Jov , C, Pan , A, Vinagre, I, L pez-Quesada, E, Meler, E, Alonso-Carril, N, Quir s, C, Amor, A, Perea, V. Pre-eclampsia is an independent predictor of atherosclerosis progression in women with type 1 diabetes: a 5 year prospective study. DIABETOLOGIA. 2025; 68DOI:. PMID:. IF:10.200(Q1/1D).
01/09/2025
Impact of cardiovascular risk factors control on atherosclerosis progression in individuals with type 1 diabetes
Vi als, C, Conget, I, Granados, M, Sol , C, Mesa, A, Ser s-Noriega, T, Perea, V, Blanco, J, Vinagre, I, Gim nez, M, Amor, A. Impact of cardiovascular risk factors control on atherosclerosis progression in individuals with type 1 diabetes. DIABETOLOGIA. 2025; 68DOI:. PMID:. IF:10.200(Q1/1D).
01/09/2025
THE HOME CARE SERVICE IN BARCELONA AS A MODEL FOR COMMUNITY-BASED CARE SERVICES: A QUALITATIVE APPROACH
Macaya, I, Ollé, L, Sánchez, E, Pérez, M, Borrell, C, Pérez, K. THE HOME CARE SERVICE IN BARCELONA AS A MODEL FOR COMMUNITY-BASED CARE SERVICES: A QUALITATIVE APPROACH. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).
01/09/2025
Phenotype Analysis of Chronic Bronchial Infection Patients on Inhaled Antibiotic Therapy: A Multicentre Retrospective Cohort Study in Spain (INBREATHING Study)
Moreno, BR, Benitez, ID, Erro, M, Burgos, J, Sayés, A, Garcia-Urrestarazu, EJ, Pou, C, Castan, RA, Navarro, A, Fuentes, AMD, Lakhani, JS, Juez-Garcia, I, Manzano, C, Santisteve, S, Morales, A, Monge, A, Moncusi-Moix, A, Sánchez-Cucó, A, Alcaide, AB, de-Torres, JP, Barbé, F, Suarez-Cuartin, G, de la Rosa, D, González, J. Phenotype Analysis of Chronic Bronchial Infection Patients on Inhaled Antibiotic Therapy: A Multicentre Retrospective Cohort Study in Spain (INBREATHING Study). ARCHIVOS DE BRONCONEUMOLOGIA. 2025; 61(9)DOI:10.1016/j.arbres.2025.04.008. PMID:40350352. IF:9.200(Q1/1D).
01/09/2025
Imaging of Immunodeficiency-Associated Lymphoproliferative Disorders
Franquet, T, Brenes, JM, Radike, M, Giménez, A, Domingo, P. Imaging of Immunodeficiency-Associated Lymphoproliferative Disorders. SEMINARS IN ULTRASOUND CT AND MRI. 2025; 46(4)DOI:10.1053/j.sult.2025.06.001. PMID:40543829. IF:1.900(Q3/6D).
01/09/2025
Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
Modest, DP, Fakih, M, Salvatore, L, Esaki, T, Lopez-Bravo, DP, Taieb, J, Karamouzis, M, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Cremolini, C, Tran, Q, Chan, E, Chao, JS, Majer, IM, Pietrantonio, F. Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. LANCET ONCOLOGY. 2025; 26(9)DOI:10.1016/S1470-2045(25)00352-3. PMID:40812325. IF:35.900(Q1/1D).
01/09/2025
Prognostic significance of genetic biomarkers in glioblastoma IDH wild-type: a retrospective survival analysis
Herrera, IC, Fabregó, IE, Cols, LC, Lladó, MC, Vidal, AG, Martín, LF, Mariscal, IE, Arango, SMR, Metrallé, SCS, Alcañiz, AG. Prognostic significance of genetic biomarkers in glioblastoma IDH wild-type: a retrospective survival analysis. VIRCHOWS ARCHIV. 2025; 487DOI:. PMID:. IF:3.100(Q2/3D).
01/09/2025
Rapcabtagene Autoleucel (YTB323) Phase 2 Trial in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Clinical
Riedell, PA, Kwon, M, Flinn, IW, Dickinson, MJ, Solano, C, Jaeger, U, Briones, J, Kato, K, Fleming, S, Bachy, E, Rambaldi, A, Shune, LO, Shah, NN, Blaise, D, Frigault, MJ, Ramakrishnan, A, Yang, A, Pearson, D, Zia, A, Segura, E, Masood, A, Barba, P. Rapcabtagene Autoleucel (YTB323) Phase 2 Trial in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Clinical. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).
01/09/2025
Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations
Jabbour, E, Recher, C, O'Nions, J, Aldoss, I, Pierola, A, Allred, A, Alonso-Dominguez, JM, Barreyro, L, Bories, P, Curtis, M, Daskalakis, N, Della Porta, MG, Döhner, H, D'Souza, A, Dugan, JP, Reyner, JE, Exum, M, Fathi, AT, Fedele, PL, Ferrante, L, Gaj, S, Garciaz, S, Garrido, A, Paniagua, SG, Guttke, C, Gyan, E, Hiebert, B, Jentzsch, M, Kantarjian, HM, Konopleva, M, Krönke, J, Kwon, MC, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Martinelli, G, Giles, DM, Murphy, J, Packman, K, Papayannidis, C, Philippar, U, Platzbecker, U, Rangaraju, S, Röllig, C, Salamero, O, Sanga, M, Sauer, T, Searle, E, Tovar, N, Tucker, T, Vallet, N, Vaughan, L, Vega, G, Vyas, P, Wei, A. Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).
01/09/2025
Monitoring Patients with Relapsing-Remitting Multiple Sclerosis Switching from Intravenous to Subcutaneous Natalizumab every 4 Weeks vs every 6 Weeks
Moreno, AA, Presas-Rodríguez, S, Gonzalez-Garcia, AM, Teniente-Sera, A, Martínez-Cáceres, EM, Querol, L, Martín-Aguilar, L, Meca-Lallana, JE, Dos Santos, CE, Millán, J, López, GV, Orgaz, ATC, Ruiz, VC, Anunciación, BAJ, Hervas, JV, Ruiz, LB, Bravo, GCA, Ramo, C. Monitoring Patients with Relapsing-Remitting Multiple Sclerosis Switching from Intravenous to Subcutaneous Natalizumab every 4 Weeks vs every 6 Weeks. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).
01/09/2025
Cracking the code: genotype-phenotype correlation models in sarcoglycanopathies
Luce, L, Kocak, G, Alonso-Pérez, J, Straub,, Töpf, A, Díaz-Manera, J. Cracking the code: genotype-phenotype correlation models in sarcoglycanopathies. NEUROMUSCULAR DISORDERS. 2025; 53DOI:. PMID:. IF:2.800(Q2/5D).
01/09/2025
Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT
Unoje, O, Hussain, Y, Habib, A, Claeys, K, Gwathmey, K, Sahagian, G, Cortés-Vicente, E, Liu, L, Jimenez, R, Patel, M, Masschaele, D, Mantegazza, R, Meisel, A, Seth, A, Attarian, S. Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT. ANNALS OF NEUROLOGY. 2025; 98DOI:. PMID:. IF:7.700(Q1/1D).
01/09/2025
HOW TO PROMOTE HEALTHY AND EQUITABLE RELATIONSHIPS IN FORMAL EDUCATION: THEORETICAL FRAMEWORK AND EDUCATIONAL PROPOSAL
Forcadell-Díez, L, Pérez, G, Fernández, A, Puig-Barrachina, V, Subirats, IG, Cortés, E, Moral, PD, Juárez, O. HOW TO PROMOTE HEALTHY AND EQUITABLE RELATIONSHIPS IN FORMAL EDUCATION: THEORETICAL FRAMEWORK AND EDUCATIONAL PROPOSAL. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).
01/09/2025
Impact of Relapse in BDNF Receptors Expression in Patients With a First Episode of Schizophrenia
Bioque, M, Llorca-Bofi, V, MacDowell, KS, Amoretti, S, Mezquida, G, Cuesta, MJ, Diaz-Caneja, CM, Ibáñez, A, Segarra, R, González-Pinto, A, Roldán, A, Sáiz, PA, Mané, A, Lobo, A, Martínez-Pinteño, A, Cano-Escalera, G, Berrocoso, E, Bernardo, M. Impact of Relapse in BDNF Receptors Expression in Patients With a First Episode of Schizophrenia. SCHIZOPHRENIA BULLETIN. 2025; 51(5)DOI:10.1093/schbul/sbaf012. PMID:39977257. IF:4.800(Q1/2D).
01/09/2025
MPOX IN PEOPLE WITH HIV AND PREP USERS DURING THE 2022 OUTBREAK, SPAIN
March-Yagüe, A, Toledo, D, Díaz, A, Godoy, P, Pérez-Martinez, O, Pericas, C, Sánchez-Migallón, A, Domínguez, A. MPOX IN PEOPLE WITH HIV AND PREP USERS DURING THE 2022 OUTBREAK, SPAIN. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).
01/09/2025
PERSONALIZATION OF COLORECTAL CANCER SCREENING BASED ON PREVIOUS NEGATIVE TESTS: HOW MANY TESTS SHOULD BE USED?
Velasco, AES, Serrano, MC, Barrufet, C, Augè, JM, Torà, I, Puig, T, Milà, MA, Serra, MS, Pust, AB. PERSONALIZATION OF COLORECTAL CANCER SCREENING BASED ON PREVIOUS NEGATIVE TESTS: HOW MANY TESTS SHOULD BE USED?. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).
01/09/2025
SOCIAL DETERMINANTS OF PROXIMITY-BASED SCHOOLING AND ACTIVE SCHOOL MOBILITY IN ADOLESCENTS IN THE CITY OF BARCELONA
Amengual-Moreno, M, Oliveras, L, Marí-Dell'Olmo, M, Sánchez-Ledesma, E, Cano, GS, Font-Ribera, L. SOCIAL DETERMINANTS OF PROXIMITY-BASED SCHOOLING AND ACTIVE SCHOOL MOBILITY IN ADOLESCENTS IN THE CITY OF BARCELONA. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).